Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
Frank Lavernia, Sarah E. Adkins & Jay H. Shubrook. (2015) Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine 127:8, pages 808-817.
Read now
Read now
Andre Scheen. (2013) Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 12:4, pages 545-557.
Read now
Read now
Shamsa Ali & Vivian Fonseca. (2013)
Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety 12:1, pages 103-109.
Read now
Read now
Marc Rendell, Andjela Drincic & Radha Andukuri. (2012)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:4, pages 553-563.
Read now
Read now
Articles from other publishers (9)
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Chengzhi Zhang & Guiying Yan. (2019) Synergistic drug combinations prediction by integrating pharmacological data. Synthetic and Systems Biotechnology 4:1, pages 67-72.
Crossref
Crossref
Laís Engroff Scheeren, Ana Isa Pedroso Marcolino, Andréa Inês Horn Adams & Clarice Madalena Bueno Rolim. (2015) Stability indicating RP-LC-PDA method for the quantitative analysis of saxagliptin in pharmaceutical dosage form. Brazilian Journal of Pharmaceutical Sciences 51:2, pages 461-466.
Crossref
Crossref
Muhammad Abdul‐Ghani, Ralph A. DeFronzo & Roy Eldor. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus
686
708
.
Wenying Yang, Xiaoping Xing, Xiaofeng Lv, Yiming Li, Jianhua Ma, Guoyue Yuan, Feifei Sun, Wei Wang, Michael Woloschak, Valentina Lukashevich, Plamen Kozlovski & Wolfgang Kothny. (2015) Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus 中国2型糖尿病患者使用磺脲类药物联合维格列汀可改善血糖控制且无低血糖及体重增加. Journal of Diabetes 7:2, pages 174-181.
Crossref
Crossref
Sri Harsha Tella, Halis Kaan Akturk & Marc Rendell. (2014) Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4:1, pages 85-101.
Crossref
Crossref
Ralph A. DeFronzo, Roy Eldor & Muhammad Abdul-Ghani. (2013) Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care 36:Supplement_2, pages S127-S138.
Crossref
Crossref
Molly G. MinzeMary S. KleinBrian T. Terrell. (2013) Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S8510.
Crossref
Crossref
Xiaohui (Sophia) Xu, Roger Demers, Huidong Gu, Lisa J. Christopher, Hong Su, Laura Cojocaru, David W. Boulton, Mark Kirby, Bruce Stouffer, William G. Humphreys & Mark E. Arnold. (2012) Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations. Journal of Chromatography B 889-890, pages 77-86.
Crossref
Crossref